Targeting Genetic Drivers of Rare Genitourinary Cancers

Video

This video reviews new studies examining the genetic drivers of three rare genitourinary cancers: von Hippel-Lindau disease, advanced papillary renal cell carcinoma, and penile cancer.

In this video, Guru Sonpavde, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, reviews three new studies involving rare genitourinary cancers: a phase II study of pazopanib in von Hippel-Lindau disease (abstract 4516), a comprehensive genomic profiling of advanced papillary renal cell carcinoma (abstract 4517), and a multiregion sequencing of penile cancer that revealed actionable mutations (abstract 4519).

Sonpavde was the discussant during a poster discussion session on the identification and targeting of genetic drivers of rare genitourinary cancers, which featured these three studies, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Related Videos
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Surbhi Sidana, MD, an expert on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.